Efanesoctocog Alfa Treatment 'Victory' for Hemophilia A Patients

A once-weekly prophylactic treatment of this investigational agent led to normal or near-normal factor VIII activity levels in most patients with severe hemophilia A.
Medscape Medical News

source https://www.medscape.com/viewarticle/988586?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?